99 reports

THE GASTROINTESTINAL AND WOMEN' S HEALTH BUSINESS SEGMENTS INCLUDE PRODUCTS FOR C.

  • Antibiotic Resistance
  • Alere Inc.
  • Cepheid
  • Hologic, Inc.
  • Roche Group

A biopharmaceutical company that focuses on developing drugs for the treatment of inflammatory and gastrointestinal diseases.

  • Antibiotic Resistance
  • Allergan plc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

CF MAINLY AFFECTS THE RESPIRATORY AND GASTROINTESTINAL TRACTS.

  • Antibiotic Resistance
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • LIST OF FIGURES

GASTROINTESTINAL INFECTIONS (CIAIS AND CDIS): ACTIVE IN OUR STUDY, WE CAME ACROSS ONE APPROVED DRUG, DIFICID, AND ONE PHASE III DRUG, CADAZOLID, THAT ARE INDICATED FOR THE TREATMENT OF CDIS.

  • Antibiotic Resistance
  • United States
  • Cempra, Inc.
  • CyDex Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.

Clinical reviews in allergy & immunology; ##(##-##): ##-##.

  • Antibiotic Resistance
  • World
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

The common infectious diseases affecting this population are urinary tract infections, skin infections, bacterial pneumonia, influenza, and gastrointestinal infections.

  • Antibiotic Resistance
  • Danaher Corporation
  • Merck & Co., Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.

WAS ## MILLION YUAN IN 2017.

  • Antibiotic Resistance
  • China
  • Demand
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd

The magnitude of the impact has been categorized as described below: Low Moderate - Medium-level impact on the market High - Negligible or no impact on the market landscape - Very high impact, with radical influence on the growth of the market ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Antibiotic Resistance
  • World
  • Abbott Laboratories, Inc.
  • bioMerieux S.A.
  • Roche Group

Develops drugs for the treatment of inflammatory and gastrointestinal diseases.

  • Antibiotic Resistance
  • China
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

Gastrointestinal Surgery; ##(##): ##-##. biophysica acta; ##(##): ##-##.

  • Antibiotic Resistance
  • Achaogen, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • The Medicines Company

You can easily book an appointment with one online.

  • Antibiotic Resistance
  • Allergan plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Other viruses that cause gastrointestinal symptoms include adenoviruses, parvoviruses and astroviruses.

  • Antibiotic Resistance
  • Cepheid
  • Getinge Group
  • Roche Group
  • STERIS Corporation

BUT EVEN IN ADULTS, THEIR USE HAS BEEN LIMITED BY GASTROINTESTINAL SIDE EFFECTS, ESPECIALLY NAUSEA.

  • Antibiotic Resistance
  • United States
  • Cempra, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

The company' s digestive health products include diagnostics and therapeutics, gastrointestinal endoscopy products, enteral feeding tubes and accessories.

  • Respiratory Monitoring
  • Eastern Europe
  • Russia
  • Forecast
  • CareFusion Corporation

PLOS ONE; ##(##): E##.

  • Antibiotic Resistance
  • World
  • Allergan plc
  • Cellceutix Corporation
  • Cempra, Inc.

Other noninfectious gastrointestinal diseases such as Crohn' s disease or ulcerative colitis must also be considered.

  • Antibiotic Resistance
  • Cepheid
  • Getinge Group
  • Pfizer Inc.
  • Roche Group
  • 5 Competitive Assessment

PLOS ONE; ##(##): E##.

  • Antibiotic Resistance
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • 5 Competitive Assessment

PLOS ONE; ##(##): E##.

  • Antibiotic Resistance
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • 5 Competitive Assessment

PLOS ONE; ##(##): E##.

  • Antibiotic Resistance
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.

Similarly, the Universities' portfolio in Phase I and Preclinical stages comprises ## and ## molecules, respectively.

  • Antibiotic Resistance
  • Vaccine
  • United States
  • World
  • Product Initiative
  • SELECTED COMPANIES MARKETING PCR/NAAT SYNDROMIC TESTS/PANELS FOR INFECTIOUS DISEASES
  • COMPANY

Gastrointestinal pathogen detection family - xTAG Gastrointestinal Pathogen Panel assay.

  • Antibiotic Resistance
  • Blood Supply
  • United States
  • World
  • Biocartis S.A.

The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Antibiotic Resistance
  • Blood Disease
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Anti-Infective
  • Antibiotic Resistance
  • World
  • Product Initiative
  • Sealife PHARMA GMBH

Seventy-five percent of the nausea was classified as mild with none reported as severe, and only one omadacycline patient discontinued treatment for gastrointestinal events.

  • Antibiotic Resistance
  • Therapy
  • United States
  • Product Initiative
  • Melinta Therapeutics, Inc.

Hoffmann-La Roche Ltd PC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Antibiotic Resistance
  • Therapy
  • United States
  • Company
  • Product Initiative

The most frequently reported adverse events in the TP-## groups were gastrointestinal, which consisted of nausea and vomiting occurring mostly in the highest dose group.

  • Antibiotic Resistance
  • Biotech
  • United States
  • Product Initiative
  • Pfenex Inc.

Wounds - Overview Wounds - Therapeutics Development PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR WOUNDS, H## 2017 NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR WOUNDS, H## 2017 Phase III ## ## Phase II ## ## Phase I ## ## IND/ CTA Filed ## ## Preclinical ## ## Discovery

  • Antibiotic Resistance
  • Healthcare
  • Wound Care
  • United States
  • Product Initiative

The most frequently reported adverse events in the TP-## groups were gastrointestinal, which consisted of nausea and vomiting occurring mostly in the highest dose group.

  • Antibiotic Resistance
  • Therapy
  • United States
  • Company
  • Product Initiative